Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843074 · ClinicalTrials.gov registry record · Phase 2
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT02843074 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 53 participants.
The verdict
NCT02843074, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- PROCEDURE autologous stem cell transplantation
- DRUG elotuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-09-21 |
| Est. Completion | 2021-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02843074
The ClinicalTrials.gov registry entry for NCT02843074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT02843074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02843074 about?
NCT02843074 is a clinical study titled "Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients". This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.
What is the current status of trial NCT02843074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2016-09-21. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT02843074?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), autologous stem cell transplantation (PROCEDURE), elotuzumab (DRUG).
Who is sponsoring clinical trial NCT02843074?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.